Common Adverse Events With Second- and Third-Line Therapies in Patients With HER2+ mBC
Joseph Gligorov, MD, discusses the potential side effects of second- and third-line therapies for patients with HER2+ metastatic breast cancer and highlights the low-toxicity profile of tucatinib when combined with trastuzumab and capecitabine.
EP: 1.Evolution of Advanced HER2+ Breast Cancer Management
EP: 2.Current Standard of Care for HER2+ Metastatic Breast Cancer (mBC)
EP: 3.The Role of Trastuzumab Deruxtecan in the Treatment of HER2+ mBC
EP: 4.Approaches to Sequencing Therapies for HER2+ mBC
EP: 5.Clinical Trial Data and Real-World Evidence on Therapy Sequencing for HER2+ mBC
EP: 6.Adverse Events Seen With Second- and Third-Line Therapies in Patients With HER2+ mBC
EP: 7.Global Perspectives: Evolution of Advanced HER2+ Breast Cancer Treatment
EP: 8.Trastuzumab Deruxtecan for Patients With HER2+ Metastatic Breast Cancer (mBC)
EP: 9.Monitoring Patients With HER2+ mBC After Discontinuing Trastuzumab Deruxtecan
EP: 10.Novel Therapies Under Investigation for HER2+ mBC
EP: 11.Treatment Sequencing Approaches for Patients With HER2+ mBC
EP: 12.French Clinical Data and Real-World Evidence on Treatment Sequencing for HER2+ mBC
Now Viewing
EP: 13.Common Adverse Events With Second- and Third-Line Therapies in Patients With HER2+ mBC
EP: 14.Treatment Approaches for Patients With HER2+ mBC and Brain Metastases
EP: 15.Novel Treatment Approaches Under Investigation for HER2+ mBC
Related Videos
Related Content
